Monopar expands NorthStar collaboration; secures Ac-225 supply & full MNPR-101 IP ownership

Monopar Therapeutics

Long-term master supply agreement for actinium-225 from NorthStar for Monopar's development and commercial programs.
Monopar acquires full ownership of MNPR-101 radiopharmaceutical platform and related jointly developed IP from NorthStar.
Both companies share ownership of filed patent application on PCTA linker with Ac-225, showing superior binding vs. DOTA.
NorthStar expected to be first commercial-scale producer of non-carrier added Ac-225 using electron accelerator technology.
No financial terms disclosed; collaboration builds on NorthStar's Ac-225 manufacturing and Monopar's preclinical results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.